Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 24;17(1):157.
doi: 10.1186/s12931-016-0473-x.

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Paul M O'Byrne  1   2 , Loretta Jacques  3 , Caroline Goldfrad  4 , Namhee Kwon  5 , Michael Perrio  6 , Louisa J Yates  5 , William W Busse  7
Affiliations

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Paul M O'Byrne et al. Respir Res. .

Abstract

Background: Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and adolescent asthma patients.

Methods: Fourteen clinical studies (six Phase II and eight Phase III) were conducted as part of the fluticasone furoate global clinical development programme in asthma. Safety data from 10 parallel-group, randomised, double-blind Phase II and III studies (including 3345 patients who received at least one dose of fluticasone furoate) were integrated to provide information on adverse events, withdrawals, laboratory assessments, vital signs and hypothalamic-pituitary-adrenal axis function. The efficacy of once-daily fluticasone furoate was evaluated in all included studies.

Results: Once-daily fluticasone furoate 100 μg and 200 μg safety profiles were consistent with those reported for other inhaled corticosteroids, and both doses consistently demonstrated efficacy versus placebo. In the integrated analysis, no dose-response relationship was observed for the overall incidence of adverse events and there were no significant effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function.

Conclusion: Once-daily fluticasone furoate 100 μg and 200 μg had acceptable safety profiles and was efficacious in adult and adolescent patients with asthma. There was no evidence of cortisol suppression at studied doses.

Trial registrations: GSK (NCT01499446/FFA20001, NCT00398645/FFA106783, NCT00766090/112202, NCT00603746/FFA109684, NCT00603278/FFA109685, NCT00603382/FFA109687, NCT01436071/115283, NCT01436110/115285, NCT01159912/112059, NCT01431950/114496, NCT01165138/HZA106827, NCT01086384/106837, NCT01134042/HZA106829 and NCT01244984/1139879).

Keywords: Adverse events; Cortisol suppression; Fluticasone furoate; Forced expiratory volume in one second; Inhaled corticosteroid; Integrated analysis; Safety.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Least squares geometric mean ratio to baseline (95% CI) in urinary free cortisol excretion at end of treatment (integrated clinical studies, urine cortisol population). Analysis performed using ANCOVA with covariates of region, study, gender, age, treatment and the log of the baseline values. Includes studies NCT00603746, NCT00603278, NCT00603382, NCT01159912, NCT01431950, NCT01165138 and NCT01134042 [–, –23, 25]. Abbreviations: ANCOVA, analysis of covariance; BD, twice daily; CI, confidence interval; FF, fluticasone furoate; FP, fluticasone propionate; LS, least squares; OD, once daily
Fig. 2
Fig. 2
Forest plots for change from baseline in trough FEV1. (a) FF 100 μg versus placebo (ITT population), and (b) FF 200 μg versus placebo (ITT population). *In study NCT01499446, the final approved inhaler for FF delivery was not used [13]. Abbreviations: FEV 1, forced expiratory volume in one second; FF, fluticasone furoate; ITT, intent-to-treat; LS, least squares; OD, once daily
Fig. 3
Fig. 3
Forest plots for change from baseline (95% CI) in percentage of rescue-free 24-h periods. (a) FF 100 μg versus placebo (ITT population), and (b) FF 200 μg versus placebo (ITT population). Abbreviations: CI, confidence interval; FF, fluticasone furoate; ITT, intent-to-treat; LS, least squares; OD, once daily
See this image and copyright information in PMC

References

    1. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). http://ginasthma.org/. Accessed 30 Sept 2015.
    1. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21:66–74. doi: 10.1183/09059180.00008111. - DOI - PMC - PubMed
    1. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1–9. doi: 10.1186/1471-2466-10-1. - DOI - PMC - PubMed
    1. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005;14:88–98. doi: 10.1016/j.pcrj.2005.01.002. - DOI - PMC - PubMed
    1. Salter M, Biggadike K, Joyce L, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–7. doi: 10.1152/ajplung.00108.2007. - DOI - PubMed

Publication types

MeSH terms

Associated data